Skip to main content
S&P 5007,703.30-0.53%DOW52,268.98-0.39%NASDAQ26,118.39-1.63%BTC$81,059.00+0.69%ETH$2,340.90+0.41%GOLD$4,042.70-0.22%OIL$100.59-2.13%
Smart Investors Daily
SID Premium
GR

NASDAQ · GRAL

GRAIL, Inc.

Healthcare · Medical - Diagnostics & Research

$157.88

Up+$0.84 (+0.53%)

Updated Oct 29, 2026, 2:28 PM

SID Score

6.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.32B
P/E ratio
-8.44
Dividend yield
0.00%
52-week range
$41.50 – $166.48
Volume
1.15M
Avg. volume
1.12M

Price performance · GRAL

GRAL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 28, 2026

GRAL closed at $157.88 after 21 trading sessions, up 12.67% for the selected period.

Last close
$157.88
Period change
+12.67%
Period low
$117.81
Period high
$157.88
Daily close
View OHLC price history
GRAL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 28, 2026$150.61$160.25$149.37$157.881.15M
Oct 27, 2026$139.07$153.26$139.01$150.611.93M
Oct 26, 2026$134.83$141.6784$132.75$139.91891.37K
Oct 23, 2026$128.115$135.94$125.00$132.55575.1K
Oct 22, 2026$133.13$133.90$123.26$127.06653.26K
Oct 21, 2026$123.875$134.91$123.20$132.60599.66K
Oct 20, 2026$120.07$128.52$118.66$124.67738.86K
Oct 19, 2026$117.68$124.50$117.58$122.42578.72K
Oct 16, 2026$134.02$136.50$117.06$117.811.31M
Oct 15, 2026$136.00$139.50$132.09$135.46701.51K
Oct 14, 2026$139.79$144.18$138.00$139.70826.63K
Oct 13, 2026$138.09$142.17$135.24$140.35703.84K
Oct 12, 2026$137.41$140.49$133.86$137.37651.11K
Oct 9, 2026$133.50$142.57$133.31$140.58774.11K
Oct 8, 2026$130.00$134.555$127.46$132.611.31M
Oct 7, 2026$134.00$139.00$130.56$132.90993.22K
Oct 6, 2026$159.43$166.475$135.80$137.282.04M
Oct 5, 2026$143.00$156.49$140.305$154.081.47M
Oct 2, 2026$135.52$143.50$134.45$143.26875.34K
Oct 1, 2026$138.23$141.54$132.04$132.561.09M
Sep 30, 2026$138.27$151.4574$136.00$140.121.92M

Latest GRAL news

The latest Smart Investors Daily articles mentioning GRAL.

Stock researchCompany · Overview

GRAL research

Overview

Company profile and research snapshot.

Company profile

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$92.50
Implied upside
—
Analysts
—
GRAL recent ratings
DateFirmRatingTarget
Oct 13, 2026TD CowenBuy—
Oct 13, 2026Morgan StanleyEqual-Weight—
Oct 2, 2026UBSBuy—
Oct 1, 2026GuggenheimBuy—
Sep 28, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

What GRAIL (GRAL)'s Canada Test Rollout Means For Shareholders

Felix Health has already announced it will offer GRAIL's Galleri multi-cancer early detection blood test to eligible adults in Ontario through virtual assessments and at-home collection, supported by data from the PATHFINDER 2 study. This partnership integrates Galleri directly into a subscription-based longevity program that already includes biomarker panels, DEXA scans and VO2 max testing. This structure could deepen recurring diagnostic usage rather than one-off test orders. The next area...

Yahoo · Oct 21, 2026

GRAIL to Announce Third Quarter 2026 Financial Results

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.

Yahoo · Oct 17, 2026

GRAIL (GRAL) Stock Sees Fair Value Lift After Analysts Back Galleri Outlook

GRAIL’s updated analyst fair value estimate has shifted from US$97.40 to US$131.30, which is a meaningful reset in how the stock is being framed. The change aligns with recent Street commentary that highlights the potential of the Galleri test, the multi cancer early detection market, and upcoming regulatory and reimbursement milestones, while still noting execution and funding risks. As you read on, you will see how this new price target fits into the broader GRAIL story and how to track the...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By